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Short communication
Erysipelothrix rhusiopathiae serotype 
15 associated with recurring pig 
erysipelas outbreaks
Priscilla F Gerber,1,2 Alasdair MacLeod,3 Tanja Opriessnig1,4
Erysipelothrix rhusiopathiae is the causative agent of pig 
erysipelas and can be associated with sporadic cases or 
larger outbreaks of septicaemia with characteristic skin 
lesions or chronic polyarthritis.1 Within the genus Erysip-
elothrix, at least 6 species (Erysipelothrix rhusiopathiae, 
Erysipelothrix tonsillarum, Erysipelothrix species strain 
1, Erysipelothrix species strain 2, Erysipelothrix species 
strain 3 and Erysipelothrix inopinata) and 28 serotypes 
(1a, 1b, 2–26 and N) have been recognised.1 E rhusi-
opathiae serotypes 1 and 2 are frequently isolated from 
clinically affected pigs, although other E rhusiopathiae 
serotypes have been sporadically associated with clin-
ical disease.1 2 While there is no experimental evidence 
that Erysipelothrix species other than E rhusiopathiae 
cause disease in pigs,3 certain Erysipelothrix species 
strains have been isolated from clinical cases4 5 and 
from condemned carcases in abattoirs.2 6 
Pig erysipelas is generally seen in adults and 
grow-finish pigs after the decline of maternal antibod-
ies.1 Humoural immunity is considered most important 
for disease prevention and vaccines containing live or 
inactivated E rhusiopathiae serotype 1 or 2 isolates are 
commonly used.7 In the UK, there are two E rhusiopathi-
ae bacterins available commercially based on serotype 
2 or serotypes 1 and 2.8
In recent years, the incidence of E rhusiopathiae in-
fection in pigs appears to have increased worldwide2 9–11 
and is also increasing in European poultry production 
systems.12 This study summarises the  findings associ-
ated with chronic E rhusiopathiae infection in a com-
mercial wean-finish pig herd in the UK (farm A) that re-
ceived piglets from an E rhusiopathiae vaccinated high 
health breeding herd free of porcine reproductive and 
respiratory syndrome virus (PRRSV) and Mycoplasma 
hyopneumoniae as monitored by serological testing in 
three-month intervals. Specifically, the breeding farm 
used a commercial E rhusiopathiae serotype 2-based 
bacterin (Porcillis Ery, Intervet UK) which was adminis-
tered to gilts twice before first service and to sows once 
at each weaning.
Farm A, a continuous flow farm with routine PCV2 
vaccination at 4  weeks of age (Ingelvac CircoFLEX, 
Boehringer Ingelheim), experienced clinical signs of 
pig erysipelas of pigs aged 18–22 weeks from Febru-
ary 2015 through August 2016 characterised by de-
layed growth and a high incidence of lameness and ear 
discolourations (Fig 1). Morbidity was approximately 
8–12 per cent during this time.
A total of 10 animals with representative clinical 
signs observed in different age groups in farm A were se-
lected by the veterinarian and euthanased for postmor-
tem examination as specified below. Three 18-week-old 
pigs that were in the hospital pen due to losing body 
condition showed interstitial pneumonia, valvular 
endocarditis with dilated hearts and enlarged joints 
with turbid fluid at necropsy. Four 22-week-old pigs, 
from a pen with severe lameness in 8  per  cent of the 
pigs, showed turbid joint liquid in several articulations 
but had no cardiac lesions. E rhusiopathiae was isolat-
ed on several occasions from the spleen, heart and joint 
swabs from the affected animals aged 18–22 weeks 
in farm A (Fig 1). Additionally, three small pigs aged 
6–10 weeks showed necrotic colitis without pulmonary 
or heart lesions, and Salmonella enterica serovar Typhi-
murium was isolated from caecum swabs from these an-
imals. This finding was unrelated to the E rhusiopathiae 
cases described in the pigs aged 18– 22 weeks. The S 
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Typhimurium could have contributed to an overall im-
munocompromised condition of the pig herd.
The E rhusiopathiae isolates were serotyped as pre-
viously described.2 Serotype 15 was identified on three 
different occasions (Fig 1). After initial onset of clinical 
signs, medicated feed containing 44 ppm lincomycin, 
44 ppm spectinomycin and 1250–2500 ppm zinc oxide 
was administered to the farm A pigs aged 4–7 weeks. In 
addition, amoxicillin was administered via the drinking 
water at eight weeks of age. At the same time, the breed-
ing herd moved to a different vaccine supplier/vaccine 
product and now used a commercial E rhusiopathiae se-
rotypes 1 and 2-based bacterin (Eryseng Parvo, Hipra, 
Spain) in gilts and sows according to the manufactur-
er’s instructions. Because of lack of clinical improve-
ment, 14-week-old farm A pigs started to be medicated 
with penicillin via feed at a concentration of 200 ppm 
in December 2015 (Fig 1). Skin lesions typical of pig er-
ysipelas were first observed in January 2016 in a few 
pigs at which time off-label vaccination with Eryseng 
was initiated in pigs aged 8–10 weeks with revaccina-
tion 2 weeks later. However, no obvious impact of the 
intervention strategies was observed.
In December 2015, 25 serum samples were collected 
from poor-doing farm A pigs aged 6–22 weeks. Ten se-
rum samples were obtained from farm B pigs aged 17–
22 weeks in March 2016 for comparison purposes. Se-
rum samples were tested for the presence of antibodies 
against E rhusiopathiae surface protective antigen (Spa)
A by an in-house fluorescent microsphere immuno-
assay.13 The positive cut-off was established at a mean 
fluorescence intensity value of 1800. On the clinically 
affected farm A, seropositive animals were first detect-
ed at 14 weeks of age and the mean anti-E rhusiopathi-
ae antibody levels increased with age, being higher in 
pigs aged 18–22 weeks (Fig 2). In contrast, healthy pigs 
from farm B aged 17–20 weeks , which received piglets 
from the same breeding herd as farm A and operated in 
an all-in-all-out system, were negative for anti-E rhusi-
opathiae antibodies (Fig 2).
The recurring E rhusiopathiae outbreaks on vaccinat-
ed farm A could indicate issues with vaccine handling 
and administration or vaccine failure. E rhusiopathiae 
strains express Spa, classified in SpaA or SpaB based 
FIG 1: Timeline of the E rhusiopathiae infection dynamics, including clinical signs, postmortem findings and intervention strategies on farm A. E 
rhusiopathiae serotype 15 was isolated in April and December 2015 and in May 2016 (red-coloured chevrons), an untypable E rhusiopathiae was isolated 
in June 2015 from pigs aged 18–22 (orange-coloured chevron) and S Typhimurium was isolated in April and June 2015 from pigs aged 6–10 weeks (green S). 
Vaccine 1 contains an E rhusiopathiae serotype 2 stain (Porcillis Ery, Intervet UK) and vaccine 2 contains serotype 1 and 2 strains (Eryseng Parvo, Hipra, 
Spain). 1Vetoquinol, active ingredient amoxcycillin. 2Zoetis, active ingredients lincomycin and spectinomycin. 3Vetoquinol, active ingredients sulfadiazine and 























Fig 2: Antibodies against E rhusiopathiae SpaA were measured in 
serum samples obtained in December 2016 before implementation of E 
rhusiopathiae vaccination in growing pigs, from pigs of different ages from 
the clinically affected farm A and the unaffected farm B. Clinical signs were 
seen in pigs between 14 and 22 weeks of age and included discoloration of 
the ears and lameness (red box). The dashed line indicates the assay cut-off.
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on phylogenetic analysis, which are associated with 
protection.14 In mouse challenge studies, recombinant 
Spa protected against virulent E rhusiopathiae strains 
containing the homologous Spa but protection varied 
against strains possessing a heterologous Spa.14 15 Se-
rotypes 1 and 2 (present in vaccines) and serotype 15 
(field isolate) all contain SpaA (data not shown) and 
cross-protection should have occurred. Vaccination with 
E rhusiopathiae serotype 2 provided protection against 
serotype 15 challenge in mice and pigs.16 Recent studies 
have also shown that commercially available vaccines 
protected mice and pigs against challenge with highly 
pathogenic serotype 1a and untypeable strains con-
taining mutations in the spa region.11 However, most 
cross-protection studies evaluate only short-term pro-
tection and acute erysipelas and the conclusions may 
not always be applicable for long-term protection and/
or chronic erysipelas.17 The breeding herd was vaccinat-
ed against E rhusiopathiae on a regular basis. A change 
of the vaccine type/supplier had no effect on the clinical 
outcomes in farm A pigs.
As clinical signs on farm A were only seen after 12–
14 weeks of age, from January 2016 onwards the pigs 
were vaccinated at 8–10 weeks of age using an inacti-
vated vaccine and revaccinated two weeks later. This 
two-dose off-label vaccination protocol however also 
failed to provide protection under the high-infectious 
pressure conditions. Alternatively, vaccine handling 
and administration issues could have occurred. As se-
roconversion due to vaccination or natural infection 
cannot be differentiated and antibody responses after 
vaccination were not assessed, the reason for the lack 
of clinical improvement after implementation of vac-
cination in the growing pigs in farm A is unknown. It 
has been shown that, in the presence of E rhusiopathi-
ae passively derived antibodies, pigs vaccinated with a 
live E rhusiopathiae vaccine at 8–10 weeks of age had 
improved antibody responses compared with pigs vac-
cinated at six weeks.18 In piglets without passively de-
rived antibodies, seroconversion occurred regardless of 
the age at vaccination.18 Passively  derived antibodies 
could potentially have decreased the efficacy of the in-
activated vaccine used in farm A, although piglets aged 
6–10 weeks were seronegative before implementing the 
vaccination programme (Fig 2) and the breeding herd 
vaccination protocol remained unchanged. Further-
more, seroconversion against E rhusiopathiae was seen 
at 14 weeks of age in farm A (Fig 2), suggesting active 
infection or recirculation at 12–13 weeks of age.13
Antimicrobial therapy can also impact the host im-
mune system.19 Specifically, after E rhusiopathiae vacci-
nation and compared with an untreated control group, 
the antibody response was lower in pigs receiving intra-
muscular doses of ceftiofur, doxycycline and tiamulin 
and higher in pigs treated intramuscularly with amoxi-
cillin or tulathromycin.19 The effects of lincomycin and 
spectinomycin administered in farm A on the response 
to E rhusiopathiae vaccination are unknown. In ad-
dition, pathogens such as PRRSV and PCV2 may also 
impair the immune system, interfere with vaccinations 
and contribute to bacterial infections. Serum samples 
from affected animals tested negative for the presence 
of antibodies against PRRSV (IDEXX PRRS X3 Ab test; 
IDEXX Laboratories) in March 2015. In December 2015, 
PCV2 DNA20 was identified in one of 25 serum samples. 
Combining these results suggests that PRRSV and PCV2 
were unlikely to have contributed to the persistence of 
the outbreak.
On farm A, E rhusiopathiae infection persisted after 
multiple antimicrobial treatments and vaccination of 
the growing pigs. Clinical signs associated with the E 
rhusiopathiae serotype 15 infection consisted of lame-
ness of various degrees and slow growth with presence 
of stunted pigs. Macroscopic lesions were limited to 
joints and the heart. Classical skin lesions1 were only 
observed in few pigs approximately 10 months after the 
initial problems had started. The reasons for the lack 
of  improvement after implementing or changing anti-
microbial treatments and vaccinations are unknown, 
but the high stocking rate and poor hygiene in the 
continuous flow of pigs likely contributed. Because of 
the inability to control the clinical disease signs, farm 
A was depopulated in July 2016, washed, disinfected, 
left empty for eight weeks and then repopulated with 
implementation of an All-In/All-Out production system. 
Clinical signs consistent with pig erysipelas were not 
observed after repopulation. Appropriate medication 
and vaccination protocols may be inefficient to con-
trol chronic erysipelas under high-infectious pressure 
settings.
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